Literature DB >> 23978506

Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology.

Jerald Z Gong1, James R Cook, Timothy C Greiner, Cyrus Hedvat, Charles E Hill, Megan S Lim, Janina A Longtine, Daniel Sabath, Y Lynn Wang.   

Abstract

Recurrent mutations in JAK2 and MPL genes are genetic hallmarks of BCR-ABL1-negative myeloproliferative neoplasms. Detection of JAK2 and MPL mutations has been incorporated into routine diagnostic algorithms for these diseases. This Special Article summarizes results from a nationwide laboratory survey of JAK2 and MPL mutation analysis. Based on the current practice pattern and the literature, this Special Article provides recommendations and guidelines for laboratory practice for detection of mutations in the JAK2 and MPL genes, including clinical manifestations for prompting the mutation analysis, current and recommended methodologies for testing the mutations, and standardization for reporting the test results. This Special Article also points to future directions for genomic testing in BCR-ABL1-negative myeloproliferative neoplasms.
Copyright © 2013 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23978506     DOI: 10.1016/j.jmoldx.2013.07.002

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  13 in total

1.  Chasing down the triple-negative myeloproliferative neoplasms: Implications for molecular diagnostics.

Authors:  Stephen E Langabeer
Journal:  JAKSTAT       Date:  2016-11-14

2.  JAK2 mutations to the fore in hereditary thrombocythemia.

Authors:  Stephen E Langabeer
Journal:  JAKSTAT       Date:  2014-10-30

3.  Molecular heterogeneity of familial myeloproliferative neoplasms revealed by analysis of the commonly acquired JAK2, CALR and MPL mutations.

Authors:  Stephen E Langabeer; Karl Haslam; Jennifer Linders; Melanie J Percy; Eibhlin Conneally; Amjad Hayat; Brian Hennessy; Maeve Leahy; Karen Murphy; Margaret Murray; Fionnuala Ni Ainle; Patrick Thornton; Jeremy Sargent
Journal:  Fam Cancer       Date:  2014-12       Impact factor: 2.375

4.  JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis.

Authors:  Madhavi Maddali; Uday Prakash Kulkarni; Niveditha Ravindra; Ekta Jajodia; Arun Kumar Arunachalam; Hemamalini Suresh; Arvind Venkatraman; Biju George; Vikram Mathews; Poonkuzhali Balasubramanian
Journal:  Ann Hematol       Date:  2020-04-10       Impact factor: 3.673

Review 5.  Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches.

Authors:  Karl Haslam; Stephen E Langabeer
Journal:  Biomed Res Int       Date:  2016-10-20       Impact factor: 3.411

Review 6.  The first report of a JAK2 V617F-positive myeloproliferative neoplasm with initial manifestation as a rare pampiniform venous plexus thrombosis and review of the literature.

Authors:  Jeremy Jacobs; Deva Sharma; Cindy Vnencak-Jones
Journal:  J Thromb Thrombolysis       Date:  2021-07-09       Impact factor: 2.300

Review 7.  Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera.

Authors:  Ruth Stuckey; María Teresa Gómez-Casares
Journal:  Int J Mol Sci       Date:  2021-05-10       Impact factor: 5.923

8.  Comparative study of different methodologies to detect the JAK2 V617F mutation in chronic BCR-ABL1 negative myeloproliferative neoplasms.

Authors:  Alline Didone; Luciana Nardinelli; Mariana Marchiani; Antonio Roberto Lancha Ruiz; Ariel Lais de Lima Costa; Ismael Severino Lima; Nathalia Moreira Santos; Sabri Saeed Sanabani; Israel Bendit
Journal:  Pract Lab Med       Date:  2015-12-14

9.  The JAK2 V617F mutation in isolated neutropenia.

Authors:  Stephen E Langabeer
Journal:  EXCLI J       Date:  2018-01-02       Impact factor: 4.068

10.  The Case for Laboratory Developed Procedures: Quality and Positive Impact on Patient Care.

Authors:  Karen L Kaul; Linda M Sabatini; Gregory J Tsongalis; Angela M Caliendo; Randall J Olsen; Edward R Ashwood; Sherri Bale; Robert Benirschke; Dean Carlow; Birgit H Funke; Wayne W Grody; Randall T Hayden; Madhuri Hegde; Elaine Lyon; Kazunori Murata; Melissa Pessin; Richard D Press; Richard B Thomson
Journal:  Acad Pathol       Date:  2017-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.